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Edited by Masayuki MiyasakaAbstract Endothelial cell (EC) lifespan controlled by the IL-1
family of cytokines is an important determinant of susceptibility
to artery wall disease. Here we show that EC lacking intracellu-
lar interleukin-1 receptor antagonist (IL-1ra) have a reduced
lifespan compared to controls. Over expression of IL-1ra en-
hanced proliferation via cyclin dependent kinase 2 activity and
retinoblastoma protein phosphorylation. This was not seen in
EC lacking IL-1 receptor 1 (IL-1 signalling ability), nor appar-
ent using other stimuli e.g. TNFa. These data suggest that IL-
1ra has a speciﬁc and receptor-dependent function to control
the growth and lifespan of EC.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The healthy, unactivated endothelium is a non-thrombo-
genic single layer of cells that lines the luminal surfaces of
blood vessels. Disturbance of endothelial integrity leads to a
variety of disease states, underlining the importance of biolog-
ical and molecular mechanisms concerned with endothelial cell
(EC) renewal and preservation.
Chronic inﬂammation, mediated by the pro-inﬂammatory
cytokine interleukin-1b (IL-1b), has a recognised role in the
pathophysiology of cardiovascular disease [1] with IL-1b
expression localised to the endothelium of atherosclerotic ves-
sels. ECs undergo a ﬁnite number of cell divisions before
growth arrest or replicative senescence; modulated in part by
IL-1. There is a marked accumulation of IL-1 in aging ECs
and antisense oligonucleotides targeted to IL-1a extend EC
lifespan [2,3], whilst addition of exogenous IL-1b inhibits the
proliferation of cultured ECs [4].
The naturally occurring antagonist, interleukin-1 receptor
antagonist (IL-1ra), blocks signalling of IL-1 by binding to
the IL-1 type 1 receptor (IL-1R1). There are both secreted
and intracellular isoforms of IL-1ra [5], the secreted form be-
stows protection in animal models of cardiovascular disease
[6] and vascular injury [7] whilst the role of the intracellular
form (the only form expressed by ECs) is unclear.*Corresponding author. Fax: +44 114 2268898.
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doi:10.1016/j.febslet.2008.02.021We have previously reported that a genetic variant of IL-1ra
is linked with reduced icIL-1ra1 production by EC [8] and a
diminished proliferative capacity by EC [9]. Other studies have
suggested a role for G1 cell cycle proteins in the IL-1 mediated
proliferation of vascular smooth muscle cells [10] and the
senescence of ECs [11]. Cyclin dependent kinase-2 (CDK2)
activity is diminished in senescent HUVEC whilst bypassing
senescence with telomerase restores CDK2 translation and
activity [11].
In this study we report that a function of icIL-1ra1 in EC is
to promote proliferation. Our data suggest that icIL-1ra1
mediates this eﬀect in EC by IL-1R1 dependent binding, mod-
ulation of G1 cell cycle proteins by increasing CDK2 activity
and retinoblastoma protein phosphorylation. It is likely that
expression of icIL-1ra could increase endothelial proliferation
and thus, re-endothelialisation after vascular injury.2. Materials and methods
2.1. Cell culture
Human umbilical vein endothelial cells (HUVEC) and mouse lung
endothelial cells (MLEC) were isolated and cultured using techniques
based on previously described methods [12,13]. This study conforms to
the principles outlined in the Declaration of Helsinki for the use of hu-
man tissue. Ethical approval for the isolation of cells from cords was
given by the North Sheﬃeld NHS Trust Local Research Ethics Com-
mittee 05/Q2308/17. IL-1ra null mice were a gift from Martin Nicklin
(Sheﬃeld) [14] and were cared for in accordance with the 1996 NIH
Guide for Care and Use of Laboratory Animals. HUVEC were cul-
tured in M199 media supplemented with 20% FBS, 100 lg/mL penicil-
lin, 100 lg/mL streptomycin, 2 mmol/L L-glutamine, 20 lg/mL
endothelial cell growth factor (ECGF) and 95 lg/mL heparin. MLEC
were cultured in DMEM supplemented with 20% FBS, penicillin,
streptomycin, L-glutamine, non-essential amino acids, ECGF and hep-
arin. EC between two and four passages were used for experiments and
quiescence was achieved by serum deprivation for 24 h.
2.2. Adenoviral infection
HUVEC and MLEC were infected with adenoviral constructs con-
taining an RSV promoter and encoding full-length human icIL-1ra1,
sIL-1ra or GFP (Gene Transfer Vector Core, Iowa). Infection was at
a multiplicity of infection (MOI) of 60 pfu/cell for 4 h in serum free
media. Expression of IL-1ra was measured by Western blot (R&D Sys-
tems), and GFP was visualised by ﬂuorescence microscopy or ﬂow
cytometry.
2.3. Proliferation and apoptosis assays
Proliferation and apoptosis of HUVEC or MLEC were measured by
Ki67 immunoreactivity, 3H thymidine incorporation, TUNEL staining
and time lapse video microscopy as previously described [9,10,15]. Qui-
escent HUVEC or MLEC, which had been infected with the appropri-
ate adenovirus construct, were stimulated with 1 ng/mL and 10 ng/mLblished by Elsevier B.V. All rights reserved.
Fig. 1. Apoptosis in murine lung endothelial cells (MLEC) from IL-
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culture media alone for 48 h.
2.4. CDK2 assay and cell cycle protein detection
EC were synchronised to G0 of the cell cycle by serum deprivation
(24 h) and proliferation induced with M199 media (20% bovine serum)
for 8 h. HUVEC were lysed with 50 mmol/L Hepes pH7.5, 250 mmol/
L NaCl, 0.1% NP40, 10 mmol/L b-glycerophosphate, 1 mmol/L NaF,
1 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl ﬂuoride, 1 mmol/L
DTT, 0.1 mmol/L sodium orthovanadate, 10 lg/mL aprotinin and
20 lmol/L leupeptin. Lysates were pre-cleared with protein-G sephar-
ose beads and CDK2 immunoprecipitated (1 lg/mL anti-CDK2 anti-
body; Santa Cruz Biotechnologies). Beads were washed twice with
lysis buﬀer and twice more with kinase buﬀer (50 mmol/L Tris–HCl
(pH 7.5), 10 mmol/L MgCl2, 1 mmol/L DTT). The beads were incu-
bated with kinase buﬀer (supplemented with 0.5lmol/L ATP, 5 lg/
mL histone-H1 and 3 lCi c32P ATP) at 30 C for 30 mi. Phosphory-
lated histone-H1 was visualised by SDS–PAGE and exposure to X-
OMAT X-ray ﬁlm.
Cell cycle protein expression was detected by Western blot analysis
using antibodies targeting CDK2 (Santa Cruz Biotechnologies), Cyclin
E (Oncogene), p21cip1/waf1 and Rb proteins (both BioSource). CDK2
activity and expression of cell cycle proteins were quantiﬁed by means
of densitometry with Syngene software.
2.5. Quantiﬁcation and statistics
Data were analysed using 2-tailed paired t-tests. A value of P < 0.05
were considered to be signiﬁcant.
1RN /mice and wild-type littermate controls. (A) Representative
cumulative apoptotic index over 24 h for MLEC from IL-1RN/
(KO) and wild-type animals. (B and C) Phase contrast micrographs of
MLEC from wild-type and IL-1RN/ mice respectively at ﬁrst
passage. Note the sparsity and senescent appearance of cells in (C)
originally seeded at the same density as cells in (B). Scale bar = 5 lm.3. Results
3.1. ECs lacking IL-1ra have an enhanced rate of apoptosis
To support our earlier ﬁndings that HUVEC with a geneti-
cally determined programme to make low levels of icIL-1ra
grow poorly in culture [9], we isolated MLEC from mice lack-
ing all forms of IL-1ra and from wild-type littermate controls
and analysed apoptosis under conditions of serum withdrawal
using time lapse video microscopy (TLVM). There was an en-
hanced rate of apoptosis in MLEC lacking IL-1ra compared to
wild-type MLEC over a 24 h period (Fig. 1A). Furthermore,
MLEC isolated from IL-1RN/ mice failed to thrive com-
pared with controls (Fig. 1B and C) and were generally unable
to survive beyond a second passage.
3.2. icIL-1ra1 suppresses the anti-proliferative eﬀects of IL-1b in
human EC and promotes cell growth
The ic form of IL-1ra is the only isoform produced by
HUVEC [8,9] therefore, we examined, in detail, the role of
icIL-1ra1 upon human EC proliferation by using adenoviral
constructs containing icIL-1ra1 or GFP. Over-expression of
icIL-1ra1 by EC was detected at 2, 4 and 8 days post-infection
with 60 pfu/cell Ad5RSVicIL-1ra (Fig. 2A) with a transfection
eﬃciency of >90% determined by the fraction of cells express-
ing GFP at 4 days post-infection with 60 pfu/cell Ad5RSVGFP
(Fig. 2B).
In subsequent experiments at 4 days post-infection with
60 pfu/cell Ad5RSVicIL-1ra1 or Ad5RSVeGFP, EC were
quiesced for 24 h in media containing 2% bovine serum and
stimulated with 1 ng/mL or 10 ng/mL IL-1b for 48 h. EC
proliferation (determined by Ki67 expression) decreased in a
dose-dependent manner with the Ad5RSVeGFP control, this
response was inhibited by over-expression of icIL-1ra1
(Fig. 3A).
To determine if this was speciﬁcally an IL-1 dependent
mechanism, the anti-proliferative eﬀect of TNFa upon EC pro-liferation was also measured (Fig. 3B). Over-expression of
icIL-1ra1 had no signiﬁcant eﬀect upon the proliferation of
TNFa stimulated cells.
We have previously shown that icIL-1ra is released from
endothelial cells [16,17]. To establish if modulation of cell cycle
proteins by EC icIL-1ra is dependent upon binding to the cell-
surface type 1 IL-1 receptor (IL-1R1), we measured 3H thymi-
dine incorporation in IL-1R1 deﬁcient and wild-type MLEC
following infection with 60 pfu/cell Ad5RSVicIL-1ra1 or
Ad5RSVeGFP. Proliferation was signiﬁcantly enhanced in
wildtype MLEC that expressed icIL-1ra1 compared to the
GFP controls (P = 0.0215). There was no change in the prolif-
eration of IL-1R1 null MLEC under similar conditions
(Fig. 3C).
3.3. icIL-1ra1 induces CDK2 activity and retinoblastoma
phosphorylation in ECs
Regulation and expression and activity of G1 and S phase
cell cycle proteins by over-expression of icIL-1ra was studied
by measuring histone-H1 phosphorylation. EC were shown
to be synchronised at G0 following serum deprivation and then
at G1/S phase following addition of EC culture media for 8 h
by measuring DNA content using propidium iodide and ﬂow
cytometry (data not shown). EC expressing icIL-1ra1 showed
greater histone-H1 phosphorylation compared with cells
expressing GFP and uninfected controls (Fig. 4A). Analysis
of cell cycle proteins by Western blot showed no signiﬁcant
changes of cyclin E, CDK2 and p21cip1/waf1 levels with icIL-
1ra1 expression as quantiﬁed by densitometry (Fig. 4B).
To determine if enhanced CDK2 activity had a role in down-
stream cell cycle signalling we measured retinoblastoma
Fig. 2. Time-course and dose response of EC following infection with
Ad5RSVicIL-1ra1 or Ad5RSVGFP. (A) Time-course of icIL-1ra
protein expression by Western blot analysis 2, 4 and 8 days post-
infection (lanes 2–4). Wells were loaded for equal protein. Lanes 1 and
5 are unstimulated EC and hrIL-1ra, respectively. (B) Expression of
GFP protein by EC following infection with Ad5RSVGFP at 0, 0.6, 6
and 60 pfu/cell. The percentage of GFP expressing cells were measured
by ﬂow cytometry analysis from a total of 10000 events. A represen-
tative experiment is shown.
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nises phosphorylated and non-phosphorylated forms. Hyper-
phosphorylation of Rb mediates the G1 to S phase transition
of the cell cycle by release of the transcription factor E2F.
As expected, given the increase in CDK2 activity (Fig. 4A),
we observed predominantly hyper-phosphorylated Rb in EC
over-expressing icIL-1ra1 and sIL-1ra. This is in comparison
to uninfected and GFP controls in which both phosphorylated
and non-phosphorylated forms of Rb were present (Fig. 4).Fig. 3. icIL-1ra1 abrogates the anti-proliferative eﬀect of IL-1b upon
EC. (A) Quiescent EC stimulated for 48 h with IL-1b (1 ng/mL or
10 ng/mL) 4 days post-infection with Ad5RSVicIL-1ra-1 or Ad5RS-
VeGFP (n = 4). Proliferation was measured as the percentage of Ki67
positive nuclei (means ± S.E.M.). Statistical analysis was a paired t-test
(P = 0.031). (B) HUVEC expressing icIL-1ra or GFP and stimulated
with 10 ng/mL or 100 ng/mL TNFa, proliferation was measured by
Ki67 detection and expressed as an index of unstimulated EC (n = 3).
Stimulation with 10 ng/mL IL-1b was used as a control. (C) IL-1R1
deﬁcient MLEC expressing icIL-1ra1 or GFP (60 pfu/cell) and
proliferation measured by 3H thymidine incorporation. Data are the
means of triplicate measurements and statistical analysis was a paired
t-test.4. Discussion
The data presented here indicate a potential mechanism for
icIL-1ra involvement in EC proliferation. We deduce that one
likely mechanism of action for icIL-1ra1 may be via its release
from EC and subsequent binding to cell-surface IL-1R1.
The ability of icIL-1ra1 to overcome a decrease in prolifera-
tion in EC induced by IL-1 is consistent with recent data in IL-
1ra deﬁcient mouse ﬁbroblasts [18] and in MLEC (shown here)
where IL-1ra null cells proliferate less well and undergo apop-
tosis at an increased rate compared to those studied at an iden-
tical timepoint from wild-type littermates. An increase in p38
and p16INK4a activation has also been shown [18] suggesting
that traversing the cell cycle is not possible in IL-1ra null ﬁbro-
blasts. Conversely, over-expression of icIL-1ra in human intes-tinal epithelial cells and keratinocytes inhibited p38 activation
[19]. In keratinocytes, this eﬀect was mediated by icIL-1ra1
interacting with the COP9 signalosome (CSN3) [20]. The
Fig. 4. icIL-1ra1 enhances CDK2 activity by EC. (A) EC expressing
GFP or icIL-1ra1 (60 pfu/cell) and synchronised to G0 were induced to
proliferate with M199 growth media for 8 h. CDK2 activity was
measured by histone-H1 phosphorylation (lanes 1–3 are control, GFP
and icIL-1ra1 transfected cells, respectively). Rb phosphorylation was
measured using a phospho-speciﬁc antibody; the upper and lower
bands are hyperphosphorylated and hypophosphorylated Rb respec-
tively (lanes 1–4 are control, GFP, icIL-1ra1 and sIL-1ra). Equal
loading is indicated by GAPDH expression. (B) Quantiﬁcation of
Histone H1 Cyclin E, CDK2, p21 and GAPDH band intensities were
measured by densitometric analysis. Data (means ± S.E.M.) are
relative units compared with GAPDH expression (n = 2).
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senescence were not studied further by these authors.
In contrast to the aforementioned studies [18,19], our work
is the ﬁrst to link the function of icIL-1ra1 to events beyond
cytoplasmic protein kinase activation, to control of the cell
cycle in human EC, and, hence, plausibly to the pathogenesis
of cardiovascular disease. These EC data contrast with the role
of IL-1 in VSMCs, where IL-1 enhances platelet-derived
growth factor-BB (PDGF-BB) cell proliferation, an eﬀect med-
iated by increased CDK2 activity [10]. Administration of IL-
1ra to these cells inhibits VSMC proliferation whilst IL-1ra
in combination with PDGF-BB enhances proliferation [10].
The data presented here indicate a potential mechanism for
icIL-1ra involvement in EC proliferation by promoting cell
cycle transition from G1 to S phase. It is likely that this is med-
iated in several ways. First, icIL-1ra1 may be released from EC
to act upon the external IL-1 receptor [16]. Second, icIL-1ra1
may act via an undeﬁned mechanism inside the cell to increasetranscription of cell cycle proteins such as cyclin D in much the
same way that has been proposed for IL-1a [21]. Third, icIL-
1ra1 could interact with signalling platforms such as CSN3
regulating multiple kinase pathways and cytokine-regulated
cell outputs [20].
Given the data presented here, that icIL-1ra1 does not mod-
ulate the proliferation of IL-1R1 null EC, we suggest that at
least in this experimental setting, icIL-1ra1 modulates prolifer-
ation by being released from EC and interacting with the
cell-surface IL-1R1 receptor. We have previously shown the
importance of IL-1R1 in the biological actions of icIL-1ra by
its ability to inhibit inﬂammatory signalling independently of
the known IL-1 intracellular signalling pathway [22]. In addi-
tion, these data support the ﬁnding that, in a mouse model
of dermal inﬂammation, icIL-1ra1 mediated eﬀects were
dependent upon IL-1R1 [23]. However, this does not necessar-
ily exclude the involvement of other intracellular mechanisms
that may also be operating at lower levels or in response to dif-
ferent micro-environmental stimuli and/or in other cell types.
In summary, the data presented here indicate that icIL-1ra1
increases EC proliferation by promoting CDK2 activity and
that this is dependent upon binding to the IL-1R1. We show
also that augmentation of icIL-1ra1 protein levels can control
EC growth via cell cycle dependent mechanisms. This is likely
to be a useful and important mechanism of action for IL-1ra
which could be of potential therapeutic value contributing to
EC protection, re-growth and thus healing in vessels after vas-
cular injury.
Acknowledgements: The authors thank Amgen for IL-1ra and Dr.
Martin Nicklin, University of Sheﬃeld for IL-1RNmice and littermate
controls.References
[1] Ross, R. (1999) Atherosclerosis is an inﬂammatory disease. Am.
Heart J. 138 (5 Pt 2), S419–S420.
[2] Garﬁnkel, S. et al. (1994) Post-transcriptional regulation of
interleukin 1 alpha in various strains of young and senescent
human umbilical vein endothelial cells. Proc. Natl. Acad. Sci.
USA 91 (4), 1559–1563.
[3] Maier, J.A. et al. (1990) Extension of the life-span of human
endothelial cells by an interleukin-1 alpha antisense oligomer.
Science 249 (4976), 1570–1574.
[4] Sawada, H., Kan, M. and McKeehan, W.L. (1990) Opposite
eﬀects of monokines (interleukin-1 and tumor necrosis factor) on
proliferation and heparin-binding (ﬁbroblast) growth factor
binding to human aortic endothelial and smooth muscle cells.
In Vitro Cell Dev. Biol. 26 (2), 213–216.
[5] Muzio, M. et al. (1999) Characterization of type II intracellular
IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. Eur. J.
Immunol. 29 (3), 781–788.
[6] Elhage, R. et al. (1998) Diﬀerential eﬀects of interleukin-1
receptor antagonist and tumor necrosis factor binding protein
on fatty-streak formation in apolipoprotein E-deﬁcient mice.
Circulation 97 (3), 242–244.
[7] Chamberlain, J. et al. (2006) Interleukin-1beta and signaling of
interleukin-1 in vascular wall and circulating cells modulates the
extent of neointima formation in mice. Am. J. Pathol. 168 (4),
1396–1403.
[8] Dewberry, R. et al. (2000) Interleukin-1 receptor antagonist
expression in human endothelial cells and atherosclerosis. Arte-
rioscler. Thromb. Vasc. Biol. 20 (11), 2394–2400.
[9] Dewberry, R.M., Crossman, D.C. and Francis, S.E. (2003)
Interleukin-1 receptor antagonist (IL-1RN) genotype modulates
the replicative capacity of human endothelial cells. Circ. Res. 92
(12), 1285–1287.
890 R.M. Dewberry et al. / FEBS Letters 582 (2008) 886–890[10] Nathe, T.J. et al. (2002) Interleukin-1beta inhibits expression of
p21(WAF1/CIP1) and p27(KIP1) and enhances proliferation in
response to platelet-derived growth factor-BB in smooth muscle
cells. Arterioscler. Thromb. Vasc. Biol. 22 (8), 1293–1298.
[11] Freedman, D.A. and Folkman, J. (2005) CDK2 translational
down-regulation during endothelial senescence. Exp. Cell Res.
307 (1), 118–130.
[12] Jaﬀe, E.A. et al. (1973) Culture of human endothelial cells derived
from umbilical veins. Identiﬁcation by morphologic and immu-
nologic criteria. J. Clin. Invest. 52 (11), 2745–2756.
[13] Dong, Q.G. et al. (1997) A general strategy for isolation of
endothelial cells from murine tissues. Characterization of two
endothelial cell lines from the murine lung and subcutaneous
sponge implants. Arterioscler. Thromb. Vasc. Biol. 17 (8), 1599–
1604.
[14] Nicklin, M.J. et al. (2000) Arterial inﬂammation in mice lacking
the interleukin 1 receptor antagonist gene. J. Exp. Med. 191 (2),
303–312.
[15] King, A.R. et al. (2003) A role for caspase-1 in serum with-
drawal-induced apoptosis of endothelial cells. Lab. Invest. 83
(10), 1497–1508.
[16] Wilson, H.L. et al. (2004) Secretion of intracellular IL-1 receptor
antagonist (type 1) is dependent on P2X7 receptor activation. J.
Immunol. 173 (2), 1202–1208.[17] Wilson, H.L. et al. (2007) P2X receptor characterization and IL-
1/IL-1Ra release from human endothelial cells. Br. J. Pharmacol.
[18] Uekawa, N. et al. (2004) Involvement of IL-1 family proteins in
p38 linked cellular senescence of mouse embryonic ﬁbroblasts.
FEBS Lett. 575 (1–3), 30–34.
[19] Garat, C. and Arend, W.P. (2003) Intracellular IL-1Ra type 1
inhibits IL-1-induced IL-6 and IL-8 production in Caco-2
intestinal epithelial cells through inhibition of p38 mitogen-
activated protein kinase and NF-kappaB pathways. Cytokine 23
(1–2), 31–40.
[20] Banda, N.K. et al. (2005) Intracellular IL-1 receptor antagonist
type 1 inhibits IL-1-induced cytokine production in keratinocytes
through binding to the third component of the COP9 signalsome.
J. Immunol. 174, 3608–3616.
[21] Werman, A. et al. (2004) The precursor form of IL-1alpha is an
intracrine pro-inﬂammatory activator of transcription. Proc.
Natl. Acad. Sci. USA 101 (8), 2434–2439.
[22] Evans, I.D.S., Francis, S.E., Crossman, D.C. and Wilson, H.L.
(2006) Action of icIL-1ra is independent of IL-1 intracellular
signalling pathway. Cytokine 33 (5), 274–280.
[23] Palmer, G. et al. (2007) Type I IL-1 receptor mediates IL-1 and
intracellular IL-1 receptor antagonist eﬀects in skin inﬂammation.
J. Invest. Dermatol. 127 (8), 1938–1946.
